A review of AbobotulinumtoxinA (Dysport)

AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. Abobotulinum...

Full description

Saved in:
Bibliographic Details
Published in:Aesthetic surgery journal 2013-03, Vol.33 (1 Suppl), p.13S-17S
Main Authors: Lorenc, Z Paul, Kenkel, Jeffrey M, Fagien, Steven, Hirmand, Haideh, Nestor, Mark S, Sclafani, Anthony P, Sykes, Jonathan M, Waldorf, Heidi A
Format: Article
Language:English
Subjects:
Botulinum Toxins, Type A - adverse effects
Botulinum Toxins, Type A - therapeutic use
Face
Humans
Neurotransmitter Agents - adverse effects
Neurotransmitter Agents - therapeutic use
Rejuvenation
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.
ISSN:1090-820X
1527-330X
DOI:10.1177/1090820X12474632